| Literature DB >> 31275424 |
Guilin Ren1, Yu Zhong2, Gang Ke3, Xiaoli Liu1, Huiting Li1, Xiaofang Li1, Qin Zheng2, Ming Yang1,2.
Abstract
The active component-target network and protein-protein interaction network of Compound Anshen essential oil were constructed. The target functions and related pathways were analyzed to explore the mechanism of Compound Anshen essential oil in the treatment of insomnia. GC-MS was used to detect the chemical composition of Compound Anshen essential oil, and the TCMSP, STITCH, TTD, and DrugBank databases were searched to predict and screen the targets of Compound Anshen essential oil in the treatment of insomnia. Cytoscape software was used to construct the network diagrams of the active component-action target and protein-protein interaction networks, ClueGO software was used to analyze the GO enrichment and KEGG pathway of the target, and the systemsDock website database was used for molecular docking. The analysis of the network results showed that the activity of Compound Anshen essential oil mainly involves biological processes such as the phospholipase C-activating G protein-coupled receptor signaling pathway, response to ammonium ions, calcium ion transport into the cytosol, and chloride transport. The results of molecular docking showed that linalool, caryophyllene, dibutyl phthalate, (-)-4-terpineol, and (-)-α-terpineol have good binding activity with ADRB2, DRD2, ESR1, KCNH2, NR1H4, NR1I2, NR1I3, and TRPV1 targets. This study demonstrates the multicomponent, multitarget, and multichannel characteristics of Compound Anshen essential oil and provides a new therapeutic idea and method for further research on the mechanism of Compound Anshen essential oil in the treatment of insomnia.Entities:
Year: 2019 PMID: 31275424 PMCID: PMC6582871 DOI: 10.1155/2019/9241403
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1GC-MS chromatogram of Compound Anshen essential oil.
Chemical composition and the topological attributes of Compound Anshen essential oil.
| No. | Composition | Degree | No. | Composition | Degree |
|---|---|---|---|---|---|
| 1 | 2-Thujene | 2 | 12 | (-)- | 17 |
| 2 |
| 9 | 13 | D-Citronellol | 1 |
| 3 |
| 3 | 14 | Linalyl anthranilate | 11 |
| 4 |
| 12 | 15 | Lavandulyl acetate | 1 |
| 5 | 3-Octanone | 5 | 16 | Caryophyllene | 22 |
| 6 | p-Cymene | 6 | 17 | (-)- | 14 |
| 7 | D-Limonene | 12 | 18 |
| 2 |
| 8 | Ocimene | 1 | 19 |
| 1 |
| 9 |
| 6 | 20 | Nonadecane | 3 |
| 10 | Linalool | 18 | 21 | Dibutyl phthalate | 29 |
| 11 | (-)-4-Terpineol | 16 | 22 | Eicosane | 1 |
Information on potential targets and the topological attributes.
| No. | Gene name | Protein name | UniProt ID | Degree |
|---|---|---|---|---|
| 1 | GABRA2 | Gamma-aminobutyric acid receptor subunit alpha-2 | P47869 | 10 |
| 2 | GABRA1 | Gamma-aminobutyric acid receptor subunit alpha-1 | P14867 | 15 |
| 3 | GABRA5 | Gamma-aminobutyric acid receptor subunit alpha-5 | P31644 | 6 |
| 4 | GABRA6 | Gamma-aminobutyric acid receptor subunit alpha-6 | Q16445 | 9 |
| 5 | ESR1 | Estrogen receptor | P03372 | 12 |
| 6 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | O75469 | 13 |
| 7 | CYP19A1 | Aromatase | P11511 | 9 |
| 8 | NR1H4 | Bile acid receptor | Q96RI1 | 9 |
| 9 | NR1I3 | Nuclear receptor subfamily 1 group I member 3 | Q14994 | 12 |
| 10 | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | 8 |
| 11 | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | 10 |
| 12 | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | 9 |
| 13 | PTGS1 | Prostaglandin G/H synthase 1 | P23219 | 7 |
| 14 | SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 | 8 |
| 15 | GABRA3 | Gamma-aminobutyric acid receptor subunit alpha-3 | P34903 | 6 |
| 16 | CYP3A4 | Cytochrome P450 3A4 | P08684 | 3 |
| 17 | HCRTR1 | Orexin receptor type 1 | O43613 | 2 |
| 18 | DRD2 | D(2) dopamine receptor | P14416 | 2 |
| 19 | ADRB2 | Beta-2 adrenergic receptor | P07550 | 5 |
| 20 | OPRD1 | Delta-type opioid receptor | P41143 | 2 |
| 21 | OPRM1 | Mu-type opioid receptor | P35372 | 2 |
| 22 | DRD1 | D(1A) dopamine receptor | P21728 | 2 |
| 23 | SMPD1 | Sphingomyelin phosphodiesterase | P17405 | 2 |
| 24 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Q8NER1 | 2 |
| 25 | ADRA1B | Alpha-1B adrenergic receptor | P35368 | 3 |
| 26 | KCNH2 | Potassium voltage-gated channel subfamily H member 2 | Q12809 | 2 |
| 27 | HTR3A | 5-hydroxytryptamine receptor 3A | P46098 | 1 |
| 28 | CALM1 | Calmodulin-1 | P0DP23 | 1 |
| 29 | SLC6A3 | Sodium-dependent dopamine transporter | Q01959 | 4 |
| 30 | ADRA1D | Alpha-1D adrenergic receptor | P25100 | 1 |
| 31 | ADRA1A | Alpha-1A adrenergic receptor | P35348 | 4 |
| 32 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | P22309 | 2 |
| 33 | SLC6A4 | Sodium-dependent serotonin transporter | P31645 | 2 |
| 34 | CA2 | Carbonic anhydrase 2 | P00918 | 1 |
| 35 | GABRA4 | Gamma-aminobutyric acid receptor subunit alpha-4 | P48169 | 1 |
| 36 | CHRNA7 | Neuronal acetylcholine receptor subunit alpha-7 | P36544 | 2 |
| 37 | HTR2A | 5-hydroxytryptamine receptor 2A | P28223 | 1 |
| 38 | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | 4 |
| 39 | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | 1 |
Figure 2Component-target network of Compound Anshen essential oil. The component-target network was built by the potential targets and active components. Targets (blue round nodes) were connected to components (green triangles).
Figure 3Protein-protein interaction network for Compound Anshen essential oil. The size and color of the nodes represent the value of the degree.
Figure 4Enriched gene ontology terms for biological process (BP) of potential targets of the main active ingredients of Compound Anshen essential oil.
Figure 5Enriched gene ontology terms for molecular function (MF) of potential targets of the main active ingredients of Compound Anshen essential oil.
Figure 6Enriched KEGG pathway of potential targets of the main active ingredients of Compound Anshen essential oil.
Figure 7Docking diagram of NR1H4 and caryophyllene, and the 2D protein-ligand interaction.